The National Institute of Health is offering a grant to fund pre-clinical studies aimed at repurposing existing experimental drugs or biologics for new therapeutic uses. The grant focuses on developing innovative methods to identify therapeutic/indication pairs, such as crowdsourcing strategies or computational algorithms. The UG3 award will support milestone-driven pre-clinical target engagement and efficacy studies, with the possibility of transitioning to UH3 for clinical trial planning. This grant opportunity closes on October 30, 2020.
Opportunity ID: 296680
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-17-465 |
| Funding Opportunity Title: | Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.350 — National Center for Advancing Translational Sciences |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 21, 2017 |
| Last Updated Date: | Apr 28, 2020 |
| Original Closing Date for Applications: | Sep 07, 2020 |
| Current Closing Date for Applications: | Oct 30, 2020 |
| Archive Date: | Nov 29, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Native American tribal governments (Federally recognized) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses County governments Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
This Funding Opportunity Announcement (FOA) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/assets/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental therapies), or use of computational algorithms. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-17-465.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| updated close date as per NOT-TR-20-025 | Apr 28, 2020 | |
| Aug 21, 2017 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-17-465 |
| Funding Opportunity Title: | Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.350 — National Center for Advancing Translational Sciences |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 21, 2017 |
| Last Updated Date: | Apr 28, 2020 |
| Original Closing Date for Applications: | Sep 07, 2020 |
| Current Closing Date for Applications: | Oct 30, 2020 |
| Archive Date: | Nov 29, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Native American tribal governments (Federally recognized) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses County governments Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
This Funding Opportunity Announcement (FOA) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/assets/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental therapies), or use of computational algorithms. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-17-465.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-17-465 |
| Funding Opportunity Title: | Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.350 — National Center for Advancing Translational Sciences |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 21, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 07, 2020 |
| Archive Date: | Oct 13, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Small businesses Private institutions of higher education Special district governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities For profit organizations other than small businesses State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/assets/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental therapies), or use of computational algorithms. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-17-465.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-D | Use for due dates on or before January 24, 2018 | PKG00234428 | Sep 30, 2017 | Jan 24, 2018 | View | |
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00236348 | Nov 16, 2017 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00260106 | Sep 30, 2017 | Oct 30, 2020 | View |
Package 1
Mandatory forms
296680 RR_SF424_2_0-2.0.pdf
296680 PHS398_CoverPageSupplement_3_0-3.0.pdf
296680 RR_OtherProjectInfo_1_3-1.3.pdf
296680 PerformanceSite_2_0-2.0.pdf
296680 RR_KeyPersonExpanded_2_0-2.0.pdf
296680 PHS398_ResearchPlan_3_0-3.0.pdf
Optional forms
296680 RR_Budget_1_3-1.3.pdf
296680 RR_SubawardBudget30_1_3-1.3.pdf
296680 PHS398_ModularBudget_1_2-1.2.pdf
296680 PHS_Inclusion_Enrollment_Report-1.0.pdf
296680 PHS_AssignmentRequestForm-1.0.pdf
Package 2
Mandatory forms
296680 RR_SF424_2_0-2.0.pdf
296680 PHS398_CoverPageSupplement_4_0-4.0.pdf
296680 RR_OtherProjectInfo_1_4-1.4.pdf
296680 PerformanceSite_2_0-2.0.pdf
296680 RR_KeyPersonExpanded_2_0-2.0.pdf
296680 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
296680 RR_Budget_1_4-1.4.pdf
296680 RR_SubawardBudget30_1_4-1.4.pdf
296680 PHS398_ModularBudget_1_2-1.2.pdf
296680 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 3
Mandatory forms
296680 RR_SF424_2_0-2.0.pdf
296680 PHS398_CoverPageSupplement_5_0-5.0.pdf
296680 RR_OtherProjectInfo_1_4-1.4.pdf
296680 PerformanceSite_2_0-2.0.pdf
296680 RR_KeyPersonExpanded_2_0-2.0.pdf
296680 PHS398_ResearchPlan_4_0-4.0.pdf
296680 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
296680 RR_Budget_1_4-1.4.pdf
296680 RR_SubawardBudget30_1_4-1.4.pdf
296680 PHS398_ModularBudget_1_2-1.2.pdf
296680 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
